Novo Nordisk

News

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering Wegovy, Mounjaro, and OTC option Orlos.

News

Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.

News

Novo Nordisk has decided to move its amycretin into pivotal trials in type 2 diabetes after a phase 2 readout.

News

GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.

News

Waltz Health is planning to disrupt the weight-loss therapy market in the US with a new direct-to-employer sales channel.